Drug Profile
Research programme: CRISPR/Cas9-based CAR-T cell therapies - Intellia Therapeutics/Novartis
Alternative Names: CRISPR/Cas9-based CAR-T cell therapies - Intellia Therapeutics/NovartisLatest Information Update: 07 Mar 2023
Price :
$50
*
At a glance
- Originator Intellia Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Congenital abnormalities
Most Recent Events
- 23 Feb 2023 Research development is still ongoing for Congenital abnormalities in the US (Intellia Therapeutics pipeline, February 2023)
- 28 Jan 2023 No recent reports of development identified for research development in Congenital-abnormalities in USA (Parenteral)
- 28 Feb 2022 The US Patent and Trademark Office issues decision in favor of Broad Institute for interference claim for patent related to CRISPR-Cas9 genome editing technology in USA